The approval of self-replicating mRNA vaccines: a dangerous precedent for health freedom

 The recent recommendation by the European Committee for Medicinal Products for Human Use (CHMP) to approve Kostaive, a self-replicating mRNA (saRNA) vaccine, marks a troubling escalation in the pharmaceutical industry’s push to deploy untested and potentially hazardous technologies on the global population. This decision, which now rests with the European Commission, raises serious concerns about the erosion of health freedom, government transparency, and the prioritization of corporate profits over public safety.

Self-replicating mRNA vaccines, such as Kostaive, are not merely another iteration of traditional mRNA technology. They represent a radical departure from conventional vaccines, introducing a mechanism that allows the injected mRNA to replicate within the body, akin to a viral infection. This “biological printing press” could theoretically amplify the vaccine’s presence and effects indefinitely, creating a cascade of unintended consequences that remain entirely unknown.

The clinical trial data for Kostaive is alarming, to say the least. Across phases 1, 2, and 3a, 90% of participants experienced adverse events after the first dose, with 74.5% reporting systemic reactions and 15.2% requiring medical attention. Five deaths were reported in the phase 3b study alone. These figures are not just statistics; they are human lives and health outcomes being sacrificed on the altar of expediency. Yet, despite these red flags, the CHMP has recommended approval, raising questions about the integrity of the regulatory process and the influence of pharmaceutical companies like Arcturus Therapeutics...<<<Read More>>>...